Cedars-Sinai Biomanufacturing vs Charles River Laboratories: CDMO Comparison
How does Cedars-Sinai Biomanufacturing compare to Charles River Laboratories?
As of Mar 2026, Cedars-Sinai Biomanufacturing: 2 FDA inspections (including 1 NAI, 1 VAI and 0 OAI). Signal Score 77.3. Charles River Laboratories: 9 FDA inspections (including 6 NAI, 3 VAI and 0 OAI), 11 EMA/MHRA GMP certificates. Signal Score 86.3. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Cedars-Sinai Biomanufacturing and Charles River Laboratories on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (9 vs 2) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Charles River Laboratories holds 9 active EMA GMP certificates; Cedars-Sinai Biomanufacturing does not appear in EudraGMDP.
- Charles River Laboratories maintains 2 MHRA / UK GMP certificates; Cedars-Sinai Biomanufacturing does not.
- Cedars-Sinai Biomanufacturing appears as a manufacturing partner on more matched clinical programs (34 vs 0) — a broader sponsor book.
Across the cross-modality scorecard, Charles River Laboratories carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Cedars-Sinai Biomanufacturing vs Charles River Laboratories
How does Cedars-Sinai Biomanufacturing compare to Charles River Laboratories?
On CDMO Signal's composite Signal Score, Cedars-Sinai Biomanufacturing is 77/100 and Charles River Laboratories is 86/100; Cedars-Sinai Biomanufacturing has 2 FDA inspections on record vs 9 for Charles River Laboratories; European coverage is 0 active EMA+MHRA certificates for Cedars-Sinai Biomanufacturing vs 11 for Charles River Laboratories. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Cedars-Sinai Biomanufacturing or Charles River Laboratories?
Both Cedars-Sinai Biomanufacturing and Charles River Laboratories maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Cedars-Sinai Biomanufacturing has 2 FDA inspections on record; Charles River Laboratories has 9.
How do Cedars-Sinai Biomanufacturing and Charles River Laboratories compare on European GMP coverage?
Cedars-Sinai Biomanufacturing holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Cedars-Sinai Biomanufacturing or Charles River Laboratories?
Cedars-Sinai Biomanufacturing is matched to 34 ClinicalTrials.gov records as a manufacturing partner; Charles River Laboratories is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
What does the Signal Score gap mean in practice?
Cedars-Sinai Biomanufacturing carries a Signal Score of 77/100 and Charles River Laboratories carries 86/100 — a small lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →